top of page

Patagonia Enters into Global Licensing Agreement with Almirall for PAT-001

Patagonia is excited to announce that we have entered into a global licensing agreement with Almirall for our lead product, PAT-001. Almirall and Patagonia Pharmaceuticals will jointly conduct development activities of Patagonia's lead product (PAT-001). Almirall will acquire global commercialization rights for such product and others that could be developed based on existing related Patagonia intellectual property.

For more information, please visit:

Featured Posts
Recent Posts
bottom of page